Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 27 December 2025 - 31 December 2025

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

NEW YORK, December 31, 2025, 11:55 ET — Regular session Shares of Cogent Biosciences slid on Wednesday, paring losses from earlier in the session, after the biotech disclosed a key regulatory filing while investors digested a cluster of insider stock sales. The stock was down 2.5% at $36.19, after touching a low of $34.33. The move comes as Cogent shifts…
31 December 2025
·····
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

NEW YORK, December 30, 2025, 15:32 ET — Regular session GRAIL Inc shares were down 3.3% at $84.95 in afternoon trading on Tuesday, after earlier touching $84.77. The early-cancer detection company is trying to turn Galleri — a multi-cancer early detection (MCED) blood test that screens for signals across many cancers from a single draw — into a mainstream part…
30 December 2025
···
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

NEW YORK, December 30, 2025, 14:30 ET — Regular session Shares of Kymera Therapeutics fell about 3% to $77.94 in afternoon trading on Tuesday, lagging a broader biotech dip. The SPDR S&P Biotech ETF was down about 1.4%, while the iShares Nasdaq Biotechnology ETF slipped about 1.1%. The pullback matters because Kymera has been one of the sector’s higher-volatility names…
30 December 2025
·····
Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

NEW YORK, December 30, 2025, 05:26 ET — Premarket Belite Bio’s U.S.-listed shares were back in focus early Tuesday after the stock surged 6.7% in the prior session, swinging between $151.50 and $169.75 before ending at $165.29. Volume was 309,235 shares, above recent daily levels for the thinly traded biotech. StockAnalysis The move matters because Belite is trying to turn…
30 December 2025
·····
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

NEW YORK, December 30, 2025, 05:21 ET — Premarket Praxis Precision Medicines Inc shares rose 13.25% on Monday to close at $304.58, after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its essential tremor candidate ulixacaltamide, a filing showed. The stock opened at $317.72 and traded between $298 and $317.72, and was down about 1% in after-hours…
30 December 2025
·····
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

NEW YORK, December 30, 2025, 01:49 ET — Market closed SELLAS Life Sciences Group Inc (SLS) shares jumped 16.7% on Monday to close at $3.35 after the company updated investors on the timing of a late-stage acute myeloid leukemia (AML) trial. The stock traded between $2.60 and $3.44 and logged about 22.4 million shares, according to StockAnalysis data. StockAnalysis The…
30 December 2025
·····
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

NEW YORK, December 30, 2025, 00:52 ET — Market closed. Praxis Precision Medicines shares climbed about 13% in Monday’s session, last trading at $304.58, after the company said U.S. regulators granted Breakthrough Therapy Designation for its experimental essential tremor treatment. The stock swung between $318.08 and $275.00 during the day. The designation, known as BTD, is an FDA pathway meant…
30 December 2025
·····
Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

NEW YORK, December 29, 2025, 23:16 ET — Market closed Mereo BioPharma Group plc shares closed down 87.65% at $0.29 on Monday after the company disclosed late-stage data that failed to hit a key fracture-rate endpoint for setrusumab, its lead rare-disease program. The stock traded between $0.20 and $0.30, with about 241 million shares changing hands, according to the company’s…
30 December 2025
····
Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx Pharmaceutical Inc shares slid on Monday after the company said two late-stage studies of setrusumab for osteogenesis imperfecta missed their primary fracture-reduction goal, prompting plans for significant expense reductions. “We are surprised and disappointed by these results,” Chief Executive Emil Kakkis said. Shares last traded down 42.3% at $19.72 after the close, versus a prior close of $34.19, after…
30 December 2025
····
Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 3:41 a.m. ET — Market closed (weekend). Regencell Bioscience Holdings Limited (NASDAQ: RGC) heads into the weekend with traders focused on one thing: volatility. RGC stock finished the last regular session (Friday) sharply lower, while the broader market logged weekly gains in a quiet, holiday-shortened week—setting up a potentially jumpy start to the next session…
28 December 2025
·····
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

NEW YORK, Dec. 27, 2025, 8:12 p.m. ET — Market closed Moderna, Inc. (NASDAQ: MRNA) stock heads into the weekend with investors parsing a mix of technical read-throughs, biotech-sector screens, and diverging Wall Street targets after a sharp pullback in the final stretch of the holiday week. Shares of Moderna ended Friday’s regular session at $31.20, down 4.73% on the…
28 December 2025
·····
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

NEW YORK, Dec. 27, 2025, 4:58 p.m. ET — Market closed (U.S. equities are shut for the weekend) CRISPR Therapeutics AG (NASDAQ: CRSP) heads into the final trading stretch of 2025 with investors balancing two forces that often define biotech stocks: headline-driven momentum and long-duration fundamental risk. The stock finished the most recent regular session (Friday, Dec. 26) at $55.08,…
27 December 2025
···
1 … 7 8 9 10 11 … 24

Stock Market Today

  • iShares Short Treasury Bond ETF (SHV) Dips Below 200-Day Moving Average
    February 2, 2026, 12:15 PM EST. Shares of iShares Short Treasury Bond ETF (SHV) fell below their 200-day moving average of $110.29 on Tuesday, dropping to $110.06. This technical indicator, commonly used by traders to assess long-term trends, signals potential shifts in market sentiment. SHV is trading near its 52-week low of $109.91 and below its 52-week high of $110.64, with the latest trade at $110.07. The ETF declined about 0.3% during the session, reflecting modest downward pressure. Such moves are watched closely by investors for clues about short-term momentum and market dynamics in Treasury-related securities.
Go toTop